Heidi Neubauer is part of the ERA PerMed funded project “JAKSTAT-target”

The project “Novel individualized therapies in JAK/STAT driven T cell malignancies” (Acronym: JAKSTAT-Target) aims to investigate the role of the JAK-STAT pathway in mature T cell lymphomas and to identify potential drugs and drug synergies targeting this pathway.

The consortium of six research groups from Vienna (Heidi Neubauer), Helsinki (Satu Mustjoki, Tero Aittokallio), Cologne (Marco Herling) and Toronto (Patrick Gunning, Benjamin Haibe-Kains) will focus on the entities of T cell prolymphocytic leukemia (T-PLL) and T cell large granular lymphocyte leukemia (T-LGLL), both showing a high incidence of missense mutations in JAK-STAT pathway genes.

The consortium, led by Satu Mustjoki, will uncover new mechanistic insights into these rare diseases and implement machine learning algorithms to predict synergistic effects from genomic, clinical and in vitro drug sensitivity data, ultimately integrating these data into clinical trials.

For more details, please visit the JAK STAT Target Consortium website, the ERA Per Med Newsletter or the affiliated Twitter profile.

March consortium meeting in Helsinki

The Moriggl Lab receives funding within the ERANET Transcan-2 initiative

The project “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T cell prolymphocytic leukemia” was funded within the European ERANET TRANSCAN-2 initiative (Horizon 2020).

The consortium consists of five research groups from Vienna (Richard Moriggl, Philipp Staber), Cologne (Marco Herling), Lyon (Emmanuel Bachy) and Dresden (Ingo Roeder). The consortium, led by Marco Herling, received €1,500,000 in funding, of which €304,720 was allocated to the group in Vienna.

Read more about the ERANET-PLL project.